Article
Diagnostic performance of three ELISAs for detection of antibodies against SARS-CoV-2 in human samples
Registro en:
MEIRA, Cássio et al. Diagnostic performance of three ELISAs for detection of antibodies against SARS-CoV-2 in human samples. Scientific World Journal, v. 2022, p. 1-7, 2022.
1537-744X
10.1155/2022/7754329
Autor
Meira, Cássio
Silva, Dahara
Santos, Ivanilson
Barreto, Breno
Rocha, Vinícius
Santos, Emanuelle
Reis, Bruna dos
Evangelista, Afrânio
Santos, Ricardo Ribeiro dos
Machado, Bruna
Ribeiro, Guilherme
Badaró, Roberto
Soares, Milena
Resumen
Departamento SENAI Nacional.
Conselho Nacional de Desenvolvimento Científico e Desenvolvimento Tecnológico (CNPq). Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection that causes coronavirus disease 2019 (COVID-19) is a disease with a high rate of transmission. Serological tests are important to perform surveys and to determine the immunological status of the population. Based on this, we evaluated three enzyme-linked immunoassays (ELISAs) using di erent antigens from SARS-CoV-2 in a cohort of 161 patients. e performance of the ELISA developed for immunoglobulin G (IgG) measurement against SARS-CoV-2 was evaluated based on sensitivity, speci city, and accuracy. We found speci cities of 0.98, 0.98, and 0.99 and sensitivities of 0.99, 0.91, and 0.87 for the nucleocapsid (N) protein, spike protein, and receptor binding domain (RBD) fraction, respectively. e accuracy assessment indicated the N protein (accuracy 0.98) as the antigen most likely to give a correct diagnosis. Overall, the antibody responses were present for all three proteins in subjects with con rmed SARS-CoV-2 infections, showing a similar pattern of antibody production for di erent antigens. In summary, these highly sensitive and speci c ELISAs,
with a more competitive price, appear to be a valid approach for the serodiagnosis of COVID-19.